Literature DB >> 32992265

Epidemiology of nontuberculous mycobacterial pulmonary disease in Europe and Japan by Delphi estimation.

Jodie A Schildkraut1, Jack Gallagher2, Kozo Morimoto3, Christoph Lange4, Charles Haworth5, R Andres Floto6, Wouter Hoefsloot7, David E Griffith8, Dirk Wagner9, Jakko van Ingen10.   

Abstract

BACKGROUND: Nontuberculous mycobacterial pulmonary disease (NTM-PD) is an emerging opportunistic infection, but basic epidemiological data are lacking in most regions. We have investigated epidemiology and diagnostic and treatment practices in five EU countries (United Kingdom, Spain, Italy, France, Germany; EU5) and Japan. STUDY
DESIGN: and methods: Annual prevalence in each country was established using a 2-round Delphi method in combination with a regional prevalence-estimation model that incorporated data obtained from a blinded physician screening survey (3154 physicians) and a real-world NTM-PD treating-physician/patient-chart observational study (619 physicians - 1429 patient charts).
RESULTS: The annual prevalence of NTM-PD was estimated at 6.2/100,000 in the EU5 and 24.9/100,000 in Japan. Overall prevalence between the EU5 was comparable, while differences in regional prevalence were found to be pronounced in France and The United Kingdom. Regional differences were also found in Japan, with the majority of cases in Chubu and Kanto regions.
CONCLUSION: This new methodology for obtaining often missing regional-level epidemiological data reveals dramatic variations in NTM-PD annual prevalence and helps pinpoint areas that may merit special preventative and treatment focus.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Epidemiology; Europe; Japan; Nontuberculous mycobacterial pulmonary disease (NTM-PD)

Mesh:

Year:  2020        PMID: 32992265     DOI: 10.1016/j.rmed.2020.106164

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  5 in total

1.  Vaccination inducing durable and robust antigen-specific Th1/Th17 immune responses contributes to prophylactic protection against Mycobacterium avium infection but is ineffective as an adjunct to antibiotic treatment in chronic disease.

Authors:  Ju Mi Lee; Jiyun Park; Steven G Reed; Rhea N Coler; Jung Joo Hong; Lee-Han Kim; Wonsik Lee; Kee Woong Kwon; Sung Jae Shin
Journal:  Virulence       Date:  2022-12       Impact factor: 5.428

2.  [Patients with lung disease caused by non-tuberculous mycobacteria in Germany: a trans-sectoral patient-oriented care concept].

Authors:  Tobias Welte; Julien Dinkel; Florian Maurer; Elvira Richter; Gernot Rohde; Carsten Schwarz; Christian Taube; Roland Diel
Journal:  Pneumologie       Date:  2022-07-25

3.  Epidemiology of infection by pulmonary non-tuberculous mycobacteria in French Guiana 2008-2018.

Authors:  Milène Chaptal; Claire Andrejak; Timothée Bonifay; Emmanuel Beillard; Geneviève Guillot; Stéphanie Guyomard-Rabenirina; Magalie Demar; Sabine Trombert-Paolantoni; Veronique Jacomo; Emilie Mosnier; Nicolas Veziris; Felix Djossou; Loïc Epelboin
Journal:  PLoS Negl Trop Dis       Date:  2022-09-09

4.  Early-Phase Adverse Effects and Management of Liposomal Amikacin Inhalation for Refractory Mycobacterium avium Complex Lung Disease in Real-World Settings.

Authors:  Atsuho Morita; Ho Namkoong; Kazuma Yagi; Takanori Asakura; Makoto Hosoya; Hiromu Tanaka; Ho Lee; Takunori Ogawa; Tatsuya Kusumoto; Shuhei Azekawa; Kensuke Nakagawara; Hirofumi Kamata; Makoto Ishii; Koichi Fukunaga; Hiroyuki Ozawa; Naoki Hasegawa
Journal:  Infect Drug Resist       Date:  2022-07-26       Impact factor: 4.177

5.  The epidemiology of nontuberculous mycobacterial pulmonary disease in the Netherlands.

Authors:  Jodie Anne Schildkraut; Sanne Maria Henriëtte Zweijpfenning; Martijn Nap; Kun He; Elena Dacheva; Jetty Overbeek; Alma Tostmann; Heiman F L Wertheim; Wouter Hoefsloot; Jakko van Ingen
Journal:  ERJ Open Res       Date:  2021-07-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.